"
Team:Georgia State
From 2014.igem.org
| Line 340: | Line 340: | ||
<!--End Clients Carousel--> | <!--End Clients Carousel--> | ||
</div> | </div> | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
</div> | </div> | ||
Revision as of 23:25, 16 October 2014
-
A Solution
that we need!This is a subheadline text sentenceSed ut perspiciatis unde omnis iste natus error sit voluptatem
accusantium doloremque laudantium, totam rem aperiam.
-
A Solution
that we need!This is a subheadline text sentenceSed ut perspiciatis unde omnis iste natus error sit voluptatem
accusantium doloremque laudantium, totam rem aperiam.
The Problem
We're finding an alternative, and ultimately non-addictive, solution that can be used in place of today's standard painkillers.
The Solution
Based on current research from leaders in the field, we're proposing the genetic modification and replication of the Mambalgin compound.
The Process
Utilizing advanced genetic engineering, we've created a unique process by which we can synthesize a new class of pain medications.
The Applications
Our research is far reaching and has the potential to completely transform the medical industry with non-addictive pain management.
Mamba: An entry into iGEM 2014
Our team from Georgia State University has been working to successfully insert and purify mambalgin, a protein component of the venom of Dendroaspis Polylepis, better known as the Black Mamba. The mambalgin peptide is a powerful analgesic that directly blocks pain transmission in the peripheral nervous system (Diochot et al, 2012) by targeting acid sensing ion channels within nociceptors beneath the epidermis. Furthermore, recombinant purification of mambalgin could assist in developing anti-venom without the attendant risk of harvesting venom directly from snakes.
From the Lab
Video Highlights
Partners & Sponsors
